Why Health Catalyst (HCAT) shares are trading lower today. Adam hejl /. August 7, 2026 What happened? Shares of healthcare data analytics company Health Catalyst (NASDAQ:HCAT) fell 23.1% in the afternoon session after the company provided a weak third-quarter revenue forecast and lowered its full-year outlook, despite topping second-quarter revenue expectations. For the upcoming third quarter, Health Catalyst expects revenue of $55.5 million, a sharp sequential decline from the $70.49 million reported for the second quarter, which itself was down 12.7% year over year. The company also reduced its full-year 2026 revenue guidance to $247.5 million at the midpoint, a 5.7% decrease from its previous forecast. This bleak outlook overshadowed the second-quarter results, in which the company's adjusted earnings per share met analysts' estimates, signaling significant challenges ahead. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Health Catalyst? Access our full analysis report here, it's free. What is the market telling us. Health Catalyst's shares are extremely volatile and have had 55 moves greater than 5% over the last year. But moves this big are rare even for Health Catalyst and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 4 days ago when the stock gained 6.4% on the news that the software sector caught a massive tailwind, fueled by easing geopolitical tensions and a fresh wave of AI-driven M&A. Over the weekend, President Trump abruptly called off a planned military offensive against Iran. Yielding to pressure from Gulf allies, the administration shifted toward diplomatic talks to reopen the Strait of Hormuz. This critical de-escalation relieved pressure on global energy markets and inflation expectations, accelerating a drop in Treasury yields. For software, this shifting macro backdrop is the perfect catalyst. Lower interest rates reduce the discount rate applied to expected future cash flows, driving capital back into growth-oriented tech equities. Furthermore, a lower-yield environment provides cheaper borrowing costs to fund ongoing AI development and the aggressive acquisitions currently sweeping the industry. Strategic dealmaking continues to accelerate. Yellow.ai, a global leader in enterprise agentic AI, announced a $550 million SPAC merger with Bluerock Acquisition Corp to go public under the ticker "YAI." Meanwhile, financial automation leader AutoRek acquired Grath to integrate its AI-driven reconciliation and compliance technology. Health Catalyst is down 24.3% since the beginning of the year, and at $1.73 per share, it is trading 53.3% below its 52-week high of $3.69 from August 2025. Investors who bought $1,000 worth of Health Catalyst's shares 5 years ago would now be looking at only $29.92. ALSO WORTH WATCHING: Nvidia's Quiet Partner. Nvidia's chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all. Every AI server needs specialized infrastructure the chip companies don't make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Health Catalyst, a healthcare data analytics company, reported Q2 2026 revenue of $70.49 million, topping analyst estimates by 2.1% despite a 12.7% year-on-year decline. The company's non-GAAP profit of $0.04 per share met expectations. However, the stock dropped 25.5% following disappointing forward guidance. Next quarter's revenue projection of $55.5 million came in 10.7% below analyst estimates, representing a 27.3% year-on-year decline. The company also lowered its full-year revenue guidance to $247.5 million from $262.5 million. Full-year EBITDA guidance of $18.25 million fell short of analyst estimates of $32.09 million. Chief executive Ben Albert said the company "delivered a very productive second quarter, exceeding the high end of our revenue guidance".

Health Catalyst investors approve directors, pay; board declassification fails. July 16, 2026 Key points. * Health Catalyst stockholders approved three of four proposals at the 2026 annual meeting, including the election of two directors, ratification of Ernst & Young as auditor, and an advisory vote on executive pay. * The only proposal that failed was the move to declassify the board; it did not receive the required 66.67% approval needed to pass. * Justin Spencer and Mathew Arens were elected as Class I directors to serve until the 2029 annual meeting, and the meeting established a quorum with 54,417,854 shares represented. * MarketBeat previews the top five stocks to own by August 1st. Health Catalyst NASDAQ: HCAT stockholders approved three of four proposals presented at the company's 2026 annual meeting, including the election of two directors, ratification of the company's auditor and an advisory vote on executive compensation. A proposal to phase out the company's classified board structure did not receive the required level of support. The virtual meeting was held July 16, 2026, and chaired by Ben Landry, Health Catalyst's general counsel. Landry said the meeting was conducted as an audio webcast in accordance with the company's bylaws and Delaware law. Stockholders of record as of the close of business on May 22, 2026, were entitled to vote. Janice W. Castillo, acting as inspector of election, reported that 54,417,854 shares were represented in person or by proxy out of 73,894,020 shares entitled to vote, establishing a quorum. Directors elected to Class I seats. Stockholders elected Justin Spencer and Mathew Arens as Class I directors. Landry said the nominees were selected by the board to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified, subject to earlier resignation or removal. Castillo reported that the two nominees received the plurality of votes properly cast, the threshold required for election. Landry also noted that the company had not received any advance notice from stockholders intending to nominate alternative director candidates, and he declared nominations closed. Auditor ratification and executive pay approved. Stockholders ratified the appointment of Ernst & Young LLP as Health Catalyst's independent registered public accounting firm for the fiscal year ending Dec. 31, 2026. Ernst & Young was represented at the meeting by Noah Van Cott. Landry said shareholder ratification of the auditor appointment was not required by the company's bylaws or otherwise, but the board submitted the matter for a vote "as a matter of good corporate governance." He said that if stockholders had not approved the selection, the audit committee would have reconsidered whether to retain Ernst & Young. He also said the audit committee may appoint a different auditor during the year if it determines a change would be in the best interests of stockholders. Discover more Cryptocurrency market updates Stockholders also approved, on an advisory and non-binding basis, the compensation of the company's named executive officers as disclosed in the proxy statement. Landry said the board would consider the outcome of the vote when determining compensation for named executive officers. Board declassification proposal fails. The only proposal that failed was a measure to restate Health Catalyst's amended and restated certificate of incorporation to phase out the classified board structure. The proposal would have provided that all directors elected on or after the 2029 annual meeting be elected annually. Landry said approval of the proposal required the affirmative vote of 66.67% of votes properly cast. Castillo reported that less than 66.67% of the votes properly cast were voted in favor of the proposal. Landry then declared that the proposal had not been approved by stockholders. No stockholder questions submitted. Landry said stockholders could submit questions related to the proposals during the formal portion of the meeting and general questions about the company after adjournment of the formal proceedings. No questions were submitted during the meeting. Landry said the final voting results, including any ballots and proxies recorded during the meeting, would be included in the inspector of election's report, entered into the meeting minutes and disclosed in Health Catalyst's filings with the Securities and Exchange Commission. About Health Catalyst (NASDAQ:HCAT). Health Catalyst NASDAQ: HCAT is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information. The core of Health Catalyst's offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources - from electronic health records to claims and patient-generated data - into a single analytics environment. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Health Catalyst, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list. While Health Catalyst currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.